Logo image of INMD

INMODE LTD (INMD) Stock Fundamental Analysis

NASDAQ:INMD - Nasdaq - IL0011595993 - Common Stock - Currency: USD

18.03  +0.53 (+3.03%)

Fundamental Rating

6

Overall INMD gets a fundamental rating of 6 out of 10. We evaluated INMD against 191 industry peers in the Health Care Equipment & Supplies industry. INMD gets an excellent profitability rating and is at the same time showing great financial health properties. INMD is cheap, but on the other hand it scores bad on growth. This makes INMD very considerable for value investing!


Dividend Valuation Growth Profitability Health

Quickly go to:

9

1. Profitability

1.1 Basic Checks

In the past year INMD was profitable.
INMD had a positive operating cash flow in the past year.
Of the past 5 years INMD 4 years were profitable.
Of the past 5 years INMD 4 years had a positive operating cash flow.
INMD Yearly Net Income VS EBIT VS OCF VS FCFINMD Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 50M 100M 150M

1.2 Ratios

Looking at the Return On Assets, with a value of 18.65%, INMD belongs to the top of the industry, outperforming 97.37% of the companies in the same industry.
Looking at the Return On Equity, with a value of 20.85%, INMD belongs to the top of the industry, outperforming 95.26% of the companies in the same industry.
INMD's Return On Invested Capital of 15.55% is amongst the best of the industry. INMD outperforms 96.32% of its industry peers.
Measured over the past 3 years, the Average Return On Invested Capital for INMD is significantly above the industry average of 8.12%.
The 3 year average ROIC (28.25%) for INMD is well above the current ROIC(15.55%). The reason for the recent decline needs to be investigated.
Industry RankSector Rank
ROA 18.65%
ROE 20.85%
ROIC 15.56%
ROA(3y)27.49%
ROA(5y)27.16%
ROE(3y)31.31%
ROE(5y)31.63%
ROIC(3y)28.25%
ROIC(5y)27.22%
INMD Yearly ROA, ROE, ROICINMD Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 10 20 30 40 50

1.3 Margins

Looking at the Profit Margin, with a value of 36.26%, INMD belongs to the top of the industry, outperforming 98.42% of the companies in the same industry.
In the last couple of years the Profit Margin of INMD has grown nicely.
INMD has a better Operating Margin (32.07%) than 98.95% of its industry peers.
INMD's Operating Margin has improved in the last couple of years.
INMD has a Gross Margin of 81.64%. This is amongst the best in the industry. INMD outperforms 94.21% of its industry peers.
In the last couple of years the Gross Margin of INMD has remained more or less at the same level.
Industry RankSector Rank
OM 32.07%
PM (TTM) 36.26%
GM 81.64%
OM growth 3Y4.03%
OM growth 5Y4.81%
PM growth 3Y3.39%
PM growth 5Y12.47%
GM growth 3Y-0.57%
GM growth 5Y-0.32%
INMD Yearly Profit, Operating, Gross MarginsINMD Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 20 40 60 80

More info and screens

7

2. Health

2.1 Basic Checks

INMD has a Return on Invested Capital (ROIC), which is well above the Cost of Capital (WACC), which means it is creating value.
There is no outstanding debt for INMD. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
INMD Yearly Shares OutstandingINMD Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 20M 40M 60M 80M
INMD Yearly Total Debt VS Total AssetsINMD Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 200M 400M 600M 800M

2.2 Solvency

INMD has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Altman-Z N/A
ROIC/WACC1.71
WACC9.11%
INMD Yearly LT Debt VS Equity VS FCFINMD Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 200M 400M 600M

2.3 Liquidity

A Current Ratio of 10.68 indicates that INMD has no problem at all paying its short term obligations.
INMD has a Current ratio of 10.68. This is amongst the best in the industry. INMD outperforms 93.68% of its industry peers.
INMD has a Quick Ratio of 9.91. This indicates that INMD is financially healthy and has no problem in meeting its short term obligations.
INMD's Quick ratio of 9.91 is amongst the best of the industry. INMD outperforms 93.68% of its industry peers.
Industry RankSector Rank
Current Ratio 10.68
Quick Ratio 9.91
INMD Yearly Current Assets VS Current LiabilitesINMD Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 200M 400M 600M 800M

More info and screens

2

3. Growth

3.1 Past

INMD shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -30.47%.
Measured over the past years, INMD shows a decrease in Earnings Per Share. The EPS has been decreasing by -4.52% on average per year.
EPS 1Y (TTM)-30.47%
EPS 3Y-4.52%
EPS 5YN/A
EPS Q2Q%-40.85%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-22.82%

3.2 Future

Based on estimates for the next years, INMD will show a quite strong growth in Earnings Per Share. The EPS will grow by 12.42% on average per year.
INMD is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 3.22% yearly.
EPS Next Y15.77%
EPS Next 2Y12.42%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year-0.75%
Revenue Next 2Y3.22%
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
INMD Yearly Revenue VS EstimatesINMD Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 100M 200M 300M 400M 500M
INMD Yearly EPS VS EstimatesINMD Yearly EPS VS EstimatesYearly EPS VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 0.5 1 1.5 2 2.5

More info and screens

9

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings ratio is 10.13, which indicates a very decent valuation of INMD.
98.42% of the companies in the same industry are more expensive than INMD, based on the Price/Earnings ratio.
INMD's Price/Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 28.47.
Based on the Price/Forward Earnings ratio of 8.75, the valuation of INMD can be described as reasonable.
Based on the Price/Forward Earnings ratio, INMD is valued cheaply inside the industry as 98.42% of the companies are valued more expensively.
INMD's Price/Forward Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 92.74.
Industry RankSector Rank
PE 10.13
Fwd PE 8.75
INMD Price Earnings VS Forward Price EarningsINMD Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60 80

4.2 Price Multiples

98.95% of the companies in the same industry are more expensive than INMD, based on the Enterprise Value to EBITDA ratio.
Based on the Price/Free Cash Flow ratio, INMD is valued cheaper than 98.95% of the companies in the same industry.
Industry RankSector Rank
P/FCF 8.54
EV/EBITDA 2.7
INMD Per share dataINMD EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 2 4 6 8

4.3 Compensation for Growth

The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
The excellent profitability rating of INMD may justify a higher PE ratio.
A more expensive valuation may be justified as INMD's earnings are expected to grow with 12.42% in the coming years.
PEG (NY)0.64
PEG (5Y)N/A
EPS Next 2Y12.42%
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

No dividends for INMD!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

INMODE LTD

NASDAQ:INMD (2/5/2025, 10:47:10 AM)

18.03

+0.53 (+3.03%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)02-04 2025-02-04/bmo
Earnings (Next)N/A N/A
Inst Owners71.77%
Inst Owner Change-4.76%
Ins Owners6.86%
Ins Owner ChangeN/A
Market Cap1.37B
Analysts78.46
Price Target21.25 (17.86%)
Short Float %8.39%
Short Ratio6.58
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-2.14%
Min EPS beat(2)-13.16%
Max EPS beat(2)8.88%
EPS beat(4)2
Avg EPS beat(4)-5.78%
Min EPS beat(4)-23.01%
Max EPS beat(4)8.88%
EPS beat(8)5
Avg EPS beat(8)0.44%
EPS beat(12)9
Avg EPS beat(12)3.72%
EPS beat(16)13
Avg EPS beat(16)7.31%
Revenue beat(2)1
Avg Revenue beat(2)-8.05%
Min Revenue beat(2)-16.64%
Max Revenue beat(2)0.53%
Revenue beat(4)1
Avg Revenue beat(4)-8.02%
Min Revenue beat(4)-16.64%
Max Revenue beat(4)0.53%
Revenue beat(8)4
Avg Revenue beat(8)-4.46%
Revenue beat(12)8
Avg Revenue beat(12)-1.01%
Revenue beat(16)12
Avg Revenue beat(16)1.13%
PT rev (1m)-2.34%
PT rev (3m)0%
EPS NQ rev (1m)-12.69%
EPS NQ rev (3m)-20.3%
EPS NY rev (1m)-2.25%
EPS NY rev (3m)-0.55%
Revenue NQ rev (1m)-6.73%
Revenue NQ rev (3m)-26.46%
Revenue NY rev (1m)-1.67%
Revenue NY rev (3m)-3.71%
Valuation
Industry RankSector Rank
PE 10.13
Fwd PE 8.75
P/S 3.24
P/FCF 8.54
P/OCF 8.52
P/B 1.87
P/tB 1.87
EV/EBITDA 2.7
EPS(TTM)1.78
EY9.87%
EPS(NY)2.06
Fwd EY11.43%
FCF(TTM)2.11
FCFY11.71%
OCF(TTM)2.12
OCFY11.74%
SpS5.56
BVpS9.66
TBVpS9.66
PEG (NY)0.64
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA 18.65%
ROE 20.85%
ROCE 18.16%
ROIC 15.56%
ROICexc 183.47%
ROICexgc 183.47%
OM 32.07%
PM (TTM) 36.26%
GM 81.64%
FCFM 38%
ROA(3y)27.49%
ROA(5y)27.16%
ROE(3y)31.31%
ROE(5y)31.63%
ROIC(3y)28.25%
ROIC(5y)27.22%
ROICexc(3y)916.5%
ROICexc(5y)N/A
ROICexgc(3y)916.5%
ROICexgc(5y)N/A
ROCE(3y)32.98%
ROCE(5y)31.78%
ROICexcg growth 3Y-75.89%
ROICexcg growth 5YN/A
ROICexc growth 3Y-75.89%
ROICexc growth 5YN/A
OM growth 3Y4.03%
OM growth 5Y4.81%
PM growth 3Y3.39%
PM growth 5Y12.47%
GM growth 3Y-0.57%
GM growth 5Y-0.32%
F-Score5
Asset Turnover0.51
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Debt/EBITDA 0
Cap/Depr 72.97%
Cap/Sales 0.1%
Interest Coverage 250
Cash Conversion 118.27%
Profit Quality 104.78%
Current Ratio 10.68
Quick Ratio 9.91
Altman-Z N/A
F-Score5
WACC9.11%
ROIC/WACC1.71
Cap/Depr(3y)173.91%
Cap/Depr(5y)176.01%
Cap/Sales(3y)0.25%
Cap/Sales(5y)0.29%
Profit Quality(3y)101.97%
Profit Quality(5y)102.3%
High Growth Momentum
Growth
EPS 1Y (TTM)-30.47%
EPS 3Y-4.52%
EPS 5YN/A
EPS Q2Q%-40.85%
EPS Next Y15.77%
EPS Next 2Y12.42%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-22.82%
Revenue Next Year-0.75%
Revenue Next 2Y3.22%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-33.47%
EBIT growth 3Y39.03%
EBIT growth 5Y44.09%
EBIT Next Year-35.44%
EBIT Next 3Y-9.42%
EBIT Next 5YN/A
FCF growth 1Y-8.52%
FCF growth 3Y30.8%
FCF growth 5Y36.99%
OCF growth 1Y-8.94%
OCF growth 3Y30.7%
OCF growth 5Y36.81%